Skip to main content
Clinical Trials/IRCT20200105046010N45
IRCT20200105046010N45Recruiting未知

In- Vivo Bioequivalence study of Bicalutamide tablet 150 mg Sobhan Oncology (Bicalutamide 150mg) with brand drug (CASODEX® 150 mg AstraZeneca ) in Iranian healthy volunteers

Sobhan Oncology Pharmaceutical CO.0 sites24 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
未知
Status
Recruiting
Sponsor
Enrollment
24

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 years to 60 years (—)
Sex
All

Inclusion Criteria

  • General health
  • Body mass index between18-28
  • Informed consent
  • Being at the age of 18-60 years old

Exclusion Criteria

  • History of cardiovascular disease
  • History of liver or kidney disease
  • Alcohol & Drug addiction
  • History of hypersensitivity

Investigators

Sponsor
Sobhan Oncology Pharmaceutical CO.

Similar Trials